Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.73 |
| ▸ | TP53 | P04637 | 2/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.73 |
| ▸ | MAPT | P10636 | 1/20 | 0.73 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.73 |
| ▸ | ACHE | P22303 | 6/20 | 0.58 |
| ▸ | ADORA3 | P0DMS8 | 11/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4450353 | 1.00 | LMNA (0.73) | LMNATP53ALDH1A1MAPTTDP1 | |
| SCHEMBL19843947 | 0.93 | LMNA (0.70) | LMNATP53ALDH1A1MAPTTDP1 | |
| SCHEMBL14264204 | 0.90 | LMNA (0.60) | LMNATP53ALDH1A1MAPTTDP1 | |
| SCHEMBL5415436 | 0.90 | LMNA (0.60) | LMNATP53ALDH1A1MAPTTDP1 | |
| SCHEMBL19837869 | 0.90 | LMNA (0.60) | LMNATP53ALDH1A1MAPTTDP1 | |
| SCHEMBL19837850 | 0.89 | LMNA (0.59) | LMNATP53ALDH1A1MAPTTDP1 | |
| SCHEMBL19837842 | 0.89 | LMNA (0.59) | LMNATP53ALDH1A1MAPTTDP1 | |
| SCHEMBL19837867 | 0.89 | LMNA (0.59) | LMNATP53ALDH1A1MAPTTDP1 | |
| SCHEMBL4213566 | 0.89 | LMNA (0.59) | LMNATP53ALDH1A1MAPTTDP1 | |
| SCHEMBL26283801 | 0.86 | LMNA (0.81) | LMNATP53ALDH1A1MAPTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180037601-A1 | Nucleoside-Based Anti-Bacterial and Anti-Protozoan Drugs | UTI LIMITED PARTNERSHIP (CA) | 2018-02-08 | — | — | US | disclosed |
| US-20180037601-A1 | Nucleoside-Based Anti-Bacterial and Anti-Protozoan Drugs | UTI LIMITED PARTNERSHIP (CA) | 2018-02-08 | — | — | US | disclosed |
| US-20080070860-A1 | Purine nucleoside analogs that are selective ligands of the purine salvage pathway enzyme adenosine phosphorylase (AP) found in bacteria and protozoa; 2-chloro-5'-deoxyadenosine; 2-chloro-6-methylpurine-5'-deoxyriboside | UTI LIMITED PARTNERSHIP (CA) | 2008-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180037601-A1 | Nucleoside-Based Anti-Bacterial and Anti-Protozoan Drugs | PNP, NUDT1, SLC29A1 | LMNA 1674/4885TP53 4696/4885ALDH1A1 2475/4885 |
| US-20080070860-A1 | Purine nucleoside analogs that are selective ligands of the purine salvage pathway enzyme adenosine phosphorylase (AP) found in bacteria and protozoa; 2-chloro-5'-deoxyadenosine; 2-chloro-6-methylpurine-5'-deoxyriboside | PNP, MTAP, TYMP | LMNA 3355/4885TP53 3805/4885ALDH1A1 1453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.